Working… Menu

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00025688
Recruitment Status : Unknown
Verified September 2006 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : August 5, 2003
Last Update Posted : July 24, 2008
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: carboplatin Drug: paclitaxel Phase 3

Detailed Description:


  • Compare the objective response rate in women treated with paclitaxel with or without carboplatin as first-line chemotherapy for metastatic breast cancer.
  • Compare the overall survival, time to disease progression, and duration of response in these patients treated with these regimens.
  • Compare the safety of these regimens in this patient population.
  • Compare the quality of life of these patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior adjuvant chemotherapy (yes vs no) and ECOG performance status (0-1 vs 2). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive paclitaxel IV over 1 hour weekly for 3 weeks.
  • Arm II:Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes weekly for 3 weeks.

Treatment in both arms continues every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, before each course during study, and then after completion of study.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 220 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Randomized, Phase II Trial of Weekly Taxol (Paclitaxel) Versus Weekly Taxol Plus Paraplatin (Carboplatin) as First-Line Chemotherapy in Patients Age 65 Years or Older With Metastatic Breast Cancer
Study Start Date : January 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed breast cancer

    • Must have clinical evidence of stage IV (M1) disease
  • HER-2/neu negative (0, 1+, or 2+ by immunohistochemistry or fluorescent in situ hybridization) OR status unknown
  • At least 1 measurable lesion

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
    • Patients with bone-only disease are not eligible
  • Ineligible if currently experiencing a complete or partial response to prior hormonal therapy
  • Patients with disease progression after prior response to hormonal therapy are eligible
  • Disease progression without prior hormonal therapy is allowed
  • Stable or asymptomatic brain metastasis allowed if:

    • Other measurable disease exists
    • Cranial irradiation completed and brain metastasis stable for at least 4 weeks before study
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status:

  • Pre- or post-menopausal

Performance status:

  • ECOG 0-2

Life expectancy:

  • At least 3 months


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 2 times ULN


  • Creatinine no greater than 2 times ULN
  • Corrected calcium less than 12 mg/dL


  • No New York Heart Association class III or IV heart disease
  • No documented myocardial infarction within the past 6 months
  • No congestive heart failure
  • No unstable angina
  • No clinically significant pericardial effusion or arrhythmia


  • No active serious infection
  • No prior significant allergic reactions to drugs containing Cremophor, such as teniposide, cyclosporine, or vitamin K
  • No clinically significant (greater than grade 1) peripheral neuropathy
  • No other serious underlying medical condition that would preclude study participation


Biologic therapy:

  • More than 6 months since prior adjuvant bone marrow or peripheral blood stem cell transplantation
  • More than 6 months since prior adjuvant monoclonal antibody therapy
  • More than 6 months since prior adjuvant vaccine therapy
  • No prior trastuzumab (Herceptin)
  • No concurrent anticancer immunotherapy


  • No prior chemotherapy for metastatic breast cancer
  • More than 6 months since prior adjuvant high-dose chemotherapy
  • More than 6 months since prior adjuvant taxanes or any other adjuvant chemotherapy
  • Prior adjuvant taxanes allowed only if administered every 3 weeks

Endocrine therapy:

  • See Disease Characteristics
  • Any number of prior hormonal therapies for metastatic breast cancer allowed

    • Patients with definite signs of progression may begin study therapy immediately after stopping hormonal therapy
  • No concurrent anticancer hormonal agents (including megestrol)


  • At least 3 weeks since prior radiotherapy (4 weeks for cranial irradiation)
  • No prior radiotherapy to 30% or more of bone marrow
  • No concurrent radiotherapy except for palliation of painful bone metastasis or pathologic fractures to the area of known lytic disease


  • At least 3 weeks since prior major surgery


  • More than 6 months since prior neoadjuvant therapy
  • No other concurrent anticancer drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00025688

Show Show 25 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Edith A. Perez, MD Mayo Clinic
Layout table for additonal information Identifier: NCT00025688    
Other Study ID Numbers: CDR0000068992
First Posted: August 5, 2003    Key Record Dates
Last Update Posted: July 24, 2008
Last Verified: September 2006
Keywords provided by National Cancer Institute (NCI):
stage IV breast cancer
recurrent breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action